1039922-08-1 Usage
Uses
Used in Chemical Industry:
3-Chloro-4-[(3,4-dichlorophenyl)methoxy]benzenamine is used as an intermediate in organic synthesis for the production of various chemical products. Its unique structure and functional groups make it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Synthesis:
3-Chloro-4-[(3,4-dichlorophenyl)methoxy]benzenamine is used as a building block in the development of new pharmaceutical compounds. Its amine and ether groups can be further modified to create a wide range of drug candidates with potential therapeutic applications.
Used in Agrochemical Production:
3-Chloro-4-[(3,4-dichlorophenyl)methoxy]benzenamine is used as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the creation of effective compounds that can protect crops from pests and diseases.
Used in Specialty Chemicals:
3-Chloro-4-[(3,4-dichlorophenyl)methoxy]benzenamine is used as a raw material in the production of specialty chemicals, such as dyes, fragrances, and polymers. Its versatility in chemical reactions enables the creation of a diverse range of products with specific properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1039922-08-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,9,9,2 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1039922-08:
(9*1)+(8*0)+(7*3)+(6*9)+(5*9)+(4*2)+(3*2)+(2*0)+(1*8)=151
151 % 10 = 1
So 1039922-08-1 is a valid CAS Registry Number.
1039922-08-1Relevant academic research and scientific papers
Milik, Sandra N.,Abdel-Aziz, Amal Kamal,Lasheen, Deena S.,Serya, Rabah A.T.,Minucci, Saverio,Abouzid, Khaled A.M.
, p. 316 - 336 (2018)
In light of the emergence of resistance against the currently available EGFR inhibitors, our study focuses on tackling this problem through the development of dual EGFR/HER2 inhibitors with improved enzymatic affinities. Guided by the binding mode of the